Compare IDEXX Laboratories, Inc. (IDXX) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Wendys Co — how do they compare? IDEXX Laboratories, Inc. trades at $554.44 (market cap $44.48B), while Wendys Co trades at $7.8 (market cap $1.50B). The key difference: IDEXX Laboratories, Inc. is far larger — about 29.7× Wendys Co's market cap, and Wendys Co pays a 7.13% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | WEN | |
|---|---|---|
Market Cap | $44.48B | $1.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $11.33 |
52-Week Low | $520.87 | $6.17 |
Enterprise Value | $45.38B | $5.31B |
Dividend Yield | — | 7.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Wendy's (WEN) trades at $7.805, up 0.58% with a bullish technical signal and recent earnings beats. The stock shows attractive valuation metrics with P/E of 10.07 and P/S of 0.68, though net margins have declined to 6.77%. Recent news highlights Project Fresh initiatives and China expansion plans, while the company maintains a $0.14 dividend payment scheduled for June 2026.
WEN presents a mixed outlook with strong valuation appeal and dividend yield offset by margin pressures and declining earnings. The stock's 28% monthly gain reflects retail investor enthusiasm, but fundamental challenges require careful monitoring of turnaround execution and competitive positioning in the crowded fast-food sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
